» Articles » PMID: 3966022

Adenocarcinoma of the Uterine Cervix: Histologic Variables Associated with Lymph Node Metastasis and Survival

Overview
Journal Obstet Gynecol
Date 1985 Jan 1
PMID 3966022
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

One hundred and two patients were treated for primary adenocarcinoma of the uterine cervix over a ten-year period from 1973 to 1982. Of these, 51 patients underwent initial surgical management that included a pelvic and para-aortic lymphadenectomy with a radical hysterectomy or a surgical staging operation. Clinical lesion size, grade, and depth of stromal invasion were correlated with lymph node metastasis and survival. The incidence of positive lymph nodes was 14.6% for stage I and 40.0% for stage II. Positive lymph nodes were documented in none of 15 patients with lesions smaller than 2 cm, 16.7% (five of 30) with 2 to 4 cm, and 82.3% (five of six) with larger than 4 cm; 5.3% of grade 1 tumors, 11.1% of grade 2, and 50.0% of grade 3. There were no lymph node metastases (zero of six) in patients with a tumor that had a depth invasion of less than 2 mm, whereas positive nodes were found in 11.1% (two of 18) patients with 2 to 5 mm of invasion, 28.6% (two of seven) with 5 to 10 mm, and 57.1% (four of seven) with greater than 10 mm of invasion. Five-year survival was 82.9% for stage I and 42.9% for stage II patients; 91.7% with negative lymph nodes, and 10% with positive nodes (P less than .0001). The size of the primary tumor (P less than .0001), tumor grade (P less than .05), and depth of invasion (P less than .05) correlated with patient survival.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study).

Nagasawa T, Shoji T, Takatori E, Kaido Y, Kagabu M, Shimizu D Cancers (Basel). 2023; 15(21).

PMID: 37958375 PMC: 10650927. DOI: 10.3390/cancers15215201.


A novel Silva pattern-based model for precisely predicting recurrence in intermediate-risk cervical adenocarcinoma patients.

Guo C, Tao X, Zhang L, Zhang Y, Hua K, Qiu J BMC Womens Health. 2022; 22(1):377.

PMID: 36114524 PMC: 9482255. DOI: 10.1186/s12905-022-01971-z.


Comparison of Outcomes and Prognostic Factors Between Early-Stage Cervical Adenocarcinoma and Adenosquamous Carcinoma Patients After Radical Surgery and Postoperative Adjuvant Radiotherapy.

Zhou Y, Wang W, Hu K, Zhang F Cancer Manag Res. 2021; 13:7597-7605.

PMID: 34675656 PMC: 8500504. DOI: 10.2147/CMAR.S329614.


Changing the Prognosis of Metastatic Cervix Uteri Adenosquamous Carcinoma through a Multimodal Approach: A Case Report.

Georgescu M, Georgescu D, Georgescu T, Serbanescu L Case Rep Oncol. 2021; 13(3):1545-1551.

PMID: 33564296 PMC: 7841737. DOI: 10.1159/000511564.


Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I-IIB.

Zhou J, Chen Y, Xu X, Yan D, Lou H Medicine (Baltimore). 2018; 97(2):e9323.

PMID: 29480826 PMC: 5943842. DOI: 10.1097/MD.0000000000009323.